EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study

Viktor Grünwald, Axel Bex, Sylvie Rottey, Cristina Suárez, Giuseppe Procopio, Guillermo Velasco, Bohuslav Melichar, Jens Bedke, Lisa Pickering, Mário Fontes-Sousa, Manuela Schmidinger, Aristotelis Bamias und 5 weitere

European Journal of Cancer · 2025-07 · 225 · 115569

DOI: 10.1016/j.ejca.2025.115569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025-07. Verfasst von Viktor Grünwald und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Recurrence, Local, Immunotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ipsen Biopharmaceuticals, Gustave Roussy, Ipsen Pharma SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsNeoplasm Recurrence, LocalImmunotherapyHumansDelphi TechniqueChemotherapy, AdjuvantImmune Checkpoint InhibitorsConsensusEurope

Stichwörter der Autor:innen

Adjuvant immunotherapyConsensusDelphiRelapseRenal cell carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, University Hospital Essen, Essen, Germany.
  • Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
  • Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Milan, Italy.
  • Department of Medical Oncology, University Hospital 12 de Octubre, Instituto de Investigación, Madrid, Spain.

Förderung

  • Ipsen Biopharmaceuticals
  • Gustave Roussy
  • Ipsen Pharma SA

Zitieren

APA

Grünwald, V., Bex, A., Rottey, S., Suárez, C., Procopio, G., Velasco, G., Melichar, B., Bedke, J., Pickering, L., Fontes-Sousa, M., Schmidinger, M., Bamias, A., Gross-Goupil, M., Porta, C., Barthélémy, P., Escudier, B., & Albiges, L. (2025). Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study. European Journal of Cancer, 225, 115569. https://doi.org/10.1016/j.ejca.2025.115569

Vancouver

Grünwald V, Bex A, Rottey S, Suárez C, Procopio G, Velasco G, et al. Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study. European Journal of Cancer. 2025;225:115569. doi:10.1016/j.ejca.2025.115569

BibTeX
@article{Grnwald2025,
  author = {Grünwald, Viktor and Bex, Axel and Rottey, Sylvie and Suárez, Cristina and Procopio, Giuseppe and Velasco, Guillermo and Melichar, Bohuslav and Bedke, Jens and Pickering, Lisa and Fontes-Sousa, Mário and Schmidinger, Manuela and Bamias, Aristotelis and Gross-Goupil, Marine and Porta, Camillo and Barthélémy, Philippe and Escudier, Bernard and Albiges, Laurence},
  title = {Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {225},
  pages = {115569},
  doi = {10.1016/j.ejca.2025.115569}
}
Kostenlos starten →